Target Name: MCM9
NCBI ID: G254394
Review Report on MCM9 Target / Biomarker Content of Review Report on MCM9 Target / Biomarker
MCM9
Other Name(s): ODG4 | DNA helicase MCM9 | DNA replication licensing factor MCM9 | dJ329L24.3 | DNA helicase MCM9 (isoform 1) | Minichromosome maintenance 9 | MCM9 variant 1 | Mini-chromosome maintenance deficient domain-containing protein 1 | hMCM9 | MCM9_HUMAN | mini-chromosome maintenance deficient domain-containing protein 1 | minichromosome maintenance 9 homologous recombination repair factor | Minichromosome maintenance 9 homologous recombination repair factor, transcript variant 1 | minichromosome maintenance complex component 9 | MCM9 variant 2 | C6orf61 | DNA helicase MCM9 (isoform 2) | dJ329L24.1 | Minichromosome maintenance 9 homologous recombination repair factor, transcript variant 2 | MCMDC1

MMP-9: A Promising Drug Target and Biomarker for Cancer

MCM9 (ODG4), a gene encoding a protein known as melanoma-associated protein 9 (MMP-9), has been identified as a potential drug target or biomarker for the treatment of melanoma. MMP-9 is a protein that is expressed in high levels in the cells of individuals with melanoma, and has been shown to promote the growth and survival of these cancer cells.

Research has also suggested that MMP-9 may play a role in the development of other types of cancer, including breast, ovarian, and prostate cancer. In addition, MMP-9 has been shown to contribute to the development of cancer-associated fibrosis, a condition in which cells become stiff and fibrotic, which can lead to a range of symptoms, including pain, discomfort, and limited mobility.

One of the challenges in studying MMP-9 is its high expression in many different types of cells, making it difficult to target specifically. However, research has identified a small molecule inhibitor that can specifically target MMP-9 and inhibit its activity. This small molecule, known as S63845, has been shown to be effective in preclinical studies in treating melanoma.

In addition to its potential as a drug target, MMP-9 has also been identified as a potential biomarker for the diagnosis and monitoring of cancer. Its high expression in many different types of cells makes it a promising indicator of disease, and its potential to be targeted by small molecules suggests that it may be possible to use it as a diagnostic or monitoring tool in the future.

Overall, MCM9 is a promising target for the treatment of melanoma and other types of cancer. Further research is needed to fully understand its role and potential as a drug and biomarker.

Protein Name: Minichromosome Maintenance 9 Homologous Recombination Repair Factor

Functions: Component of the MCM8-MCM9 complex, a complex involved in the repair of double-stranded DNA breaks (DBSs) and DNA interstrand cross-links (ICLs) by homologous recombination (HR) (PubMed:23401855). Required for DNA resection by the MRE11-RAD50-NBN/NBS1 (MRN) complex by recruiting the MRN complex to the repair site and by promoting the complex nuclease activity (PubMed:26215093). Probably by regulating the localization of the MRN complex, indirectly regulates the recruitment of downstream effector RAD51 to DNA damage sites including DBSs and ICLs (PubMed:23401855). Acts as a helicase in DNA mismatch repair (MMR) following DNA replication errors to unwind the mismatch containing DNA strand (PubMed:26300262). In addition, recruits MLH1, a component of the MMR complex, to chromatin (PubMed:26300262). The MCM8-MCM9 complex is dispensable for DNA replication and S phase progression (PubMed:23401855). Probably by regulating HR, plays a key role during gametogenesis (By similarity)

The "MCM9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCM9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9 | MEI1 | MEI4 | MEIG1